{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:21:09Z","timestamp":1790205669267,"version":"4.1.0"},"reference-count":116,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003086","name":"Consejer\u00eda de Educaci\u00f3n, Universidades e Investigaci\u00f3n of Gobierno Vasco-Eusko Jaurlaritza","doi-asserted-by":"publisher","award":["GIC15\/78 IT-990-16\/IT1607-22"],"award-info":[{"award-number":["GIC15\/78 IT-990-16\/IT1607-22"]}],"id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003086","name":"Consejer\u00eda de Educaci\u00f3n, Universidades e Investigaci\u00f3n of Gobierno Vasco-Eusko Jaurlaritza","doi-asserted-by":"publisher","award":["PID2020-117983RB-I00"],"award-info":[{"award-number":["PID2020-117983RB-I00"]}],"id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Spanish Ministry of Science and Innovation","doi-asserted-by":"publisher","award":["GIC15\/78 IT-990-16\/IT1607-22"],"award-info":[{"award-number":["GIC15\/78 IT-990-16\/IT1607-22"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Spanish Ministry of Science and Innovation","doi-asserted-by":"publisher","award":["PID2020-117983RB-I00"],"award-info":[{"award-number":["PID2020-117983RB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>The study of the pharmacological properties of an antifungal agent integrates the drug pharmacokinetics, the fungal growth inhibition, the fungicidal effect and the postantifungal activity, laying the basis to guide optimal dosing regimen selection. The current manuscript reviews concepts regarding the postantifungal effect (PAFE) of the main classes of drugs used to treat Candida infections or candidiasis. The existence of PAFE and its magnitude are highly dependent on both the fungal species and the class of the antifungal agent. Therefore, the aim of this article was to compile the information described in the literature concerning the PAFE of polyenes, azoles and echinocandins against the Candida species of medical interest. In addition, the mechanisms involved in these phenomena, methods of study, and finally, the clinical applicability of these studies relating to the design of dosing regimens were reviewed and discussed. Additionally, different factors that could determine the variability in the PAFE were described. Most PAFE studies were conducted in vitro, and a scarcity of PAFE studies in animal models was observed. It can be stated that the echinocandins cause the most prolonged PAFE, followed by polyenes and azoles. In the case of the triazoles, it is worth noting the inconsistency found between in vitro and in vivo studies.<\/jats:p>","DOI":"10.3390\/jof8070727","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T20:52:41Z","timestamp":1657659161000},"page":"727","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Postantifungal Effect of Antifungal Drugs against Candida: What Do We Know and How Can We Apply This Knowledge in the Clinical Setting?"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8738-0901","authenticated-orcid":false,"given":"Nerea","family":"Jauregizar","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV\/EHU), 48940 Bilbao, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0438-2248","authenticated-orcid":false,"given":"Guillermo","family":"Quind\u00f3s","sequence":"additional","affiliation":[{"name":"Department of Immunology, Microbiology and Parasitology, Faculty of Medicine and Nursing, University of the Basque Country (UPV\/EHU), 48940 Bilbao, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Gil-Alonso","sequence":"additional","affiliation":[{"name":"Department of Immunology, Microbiology and Parasitology, Faculty of Medicine and Nursing, University of the Basque Country (UPV\/EHU), 48940 Bilbao, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6683-4847","authenticated-orcid":false,"given":"Elena","family":"Su\u00e1rez","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV\/EHU), 48940 Bilbao, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Sevillano","sequence":"additional","affiliation":[{"name":"Department of Immunology, Microbiology and Parasitology, Faculty of Medicine and Nursing, University of the Basque Country (UPV\/EHU), 48940 Bilbao, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9043-9265","authenticated-orcid":false,"given":"Elena","family":"Eraso","sequence":"additional","affiliation":[{"name":"Department of Immunology, Microbiology and Parasitology, Faculty of Medicine and Nursing, University of the Basque Country (UPV\/EHU), 48940 Bilbao, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"key":"ref_1","unstructured":"Quind\u00f3s, G. (2015). Micolog\u00eda M\u00e9dica, Elsevier. [1st ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1128\/AAC.01337-06","article-title":"Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/13693786.2012.697198","article-title":"Postantifungal effect of the combination of caspofungin with voriconazole and amphotericin B against clinical Candida krusei isolates","volume":"51","author":"Oz","year":"2013","journal-title":"Med. Mycol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1128\/AAC.46.12.4016-4018.2002","article-title":"New automated method for determining postantifungal effect of amphotericin B against Candida species: Effects of concentration, exposure time, and area under the curve","volume":"46","author":"Chryssanthou","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1601-0825.1998.tb00290.x","article-title":"The postantifungal effect (PAFE) of antimycotics on oral C. albicans isolates and its impact on candidal adhesion","volume":"4","author":"Ellepola","year":"1998","journal-title":"Oral Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1034\/j.1600-0714.2001.030008481.x","article-title":"Post-antifungal effect of polyene, azole and DNA-analogue agents against oral Candida albicans and Candida tropicalis isolates in HIV disease","volume":"30","author":"Anil","year":"2001","journal-title":"J. Oral Pathol. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1128\/JCM.39.7.2732-2735.2001","article-title":"Effects of two different growth media on the postantifungal effect induced by polyenes on Candida species","volume":"39","author":"Shu","year":"2001","journal-title":"J. Clin. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1179\/joc.2007.19.1.101","article-title":"Changes in some Candida albicans virulence factors due to amphotericin-B post-antifungal effect","volume":"19","author":"Ozkutuk","year":"2007","journal-title":"J. Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1159\/000339080","article-title":"Amphotericin B-induced in vitro postantifungal effect on Candida species of oral origin","volume":"21","author":"Ellepola","year":"2012","journal-title":"Med. Princ. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/myc.12102","article-title":"The postantifungal effect of nystatin and its impact on adhesion attributes of oral Candida dubliniensis isolates","volume":"57","author":"Ellepola","year":"2014","journal-title":"Mycoses"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/myc.12353","article-title":"In vitro postantifungal effect, adhesion traits and haemolysin production of Candida dubliniensis isolates following exposure to 5-fluorocytosine","volume":"58","author":"Ellepola","year":"2015","journal-title":"Mycoses"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jicd.12095","article-title":"Post-antifungal effect and adhesion to buccal epithelial cells of oral Candida dubliniensis isolates subsequent to limited exposure to amphotericin B, ketoconazole and fluconazole","volume":"6","author":"Ellepola","year":"2015","journal-title":"J. Investig. Clin. Dent."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/1348-0421.12362","article-title":"Caspofungin-induced in-vitro post-antifungal effect and its impact on adhesion related traits of oral Candida dubliniensis and Candida albicans isolates","volume":"60","author":"Ellepola","year":"2016","journal-title":"Microbiol. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1159\/000501764","article-title":"In vitro Post-Antifungal Effect of Posaconazole and Its Impact on Adhesion-Related Traits and Hemolysin Production of Oral Candida dubliniensis isolates","volume":"28","author":"Ellepola","year":"2019","journal-title":"Med. Princ. Pract."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1128\/AAC.44.4.1108-1111.2000","article-title":"Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans","volume":"44","author":"Ernst","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1128\/AAC.45.7.2018-2022.2001","article-title":"Influence of human serum on antifungal pharmacodynamics with Candida albicans","volume":"45","author":"Zhanel","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/jinf.2002.1042","article-title":"Postantifungal effect and effects of sub-MIC concentrations on previously treated Candida sp. Influence of growth phase","volume":"45","author":"Llorente","year":"2002","journal-title":"J. Infect."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/00365540110080340","article-title":"Post-antifungal effect and effects of sub-MIC concentrations on previously treated Candida spp.: Influence of exposure time and concentration","volume":"34","author":"Llorente","year":"2002","journal-title":"Scand. J. Infect Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1128\/AAC.48.11.4453-4456.2004","article-title":"In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies","volume":"48","author":"Spedicato","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/jac\/dkh066","article-title":"A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans","volume":"53","author":"Manavathu","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1128\/AAC.00291-06","article-title":"Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments","volume":"50","author":"Clancy","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1128\/AAC.00308-07","article-title":"Measurement of voriconazole activity against Candida albicans, C. glabrata, and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography","volume":"51","author":"Li","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1128\/AAC.01480-08","article-title":"Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates","volume":"53","author":"Nguyen","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijantimicag.2009.09.003","article-title":"Characterising the post-antifungal effects of micafungin against Candida albicans, Candida glabrata, Candida parapsilosis and Candida krusei isolates","volume":"35","author":"Nguyen","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1128\/AAC.00095-11","article-title":"Five-minute exposure to caspofungin results in prolonged postantifungal effects and eliminates the paradoxical growth of Candida albicans","volume":"55","author":"Shields","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.diagmicrobio.2011.06.018","article-title":"Post-antifungal effects and time-kill studies of anidulafungin, caspofungin, and micafungin against Candida glabrata and Candida parapsilosis","volume":"71","author":"Smith","year":"2011","journal-title":"Diagn. Microbiol. Infect Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2217\/fmb.12.31","article-title":"The postantifungal and paradoxical effects of echinocandins against Candida spp.","volume":"7","author":"Moriyama","year":"2012","journal-title":"Future Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11046-014-9799-4","article-title":"Killing rates for caspofungin against Candida albicans after brief and continuous caspofungin exposure in the presence and absence of serum","volume":"178","author":"Kovacs","year":"2014","journal-title":"Mycopathologia"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Gil-Alonso, S., Jauregizar, N., Eraso, E., and Quind\u00f3s, G. (2015). Postantifungal effect of micafungin against the species complexes of Candida albicans and Candida parapsilosis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0132730"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.diagmicrobio.2016.07.011","article-title":"Postantifungal effect of caspofungin against the Candida albicans and Candida parapsilosis clades","volume":"86","author":"Jauregizar","year":"2016","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_31","first-page":"286","article-title":"Postantifungal effect of micafungin against Candida albicans, Candida dubliniensis and Candida Africana in the presence and absence of serum","volume":"40","author":"Kardos","year":"2017","journal-title":"New Microbiol."},{"key":"ref_32","first-page":"183","article-title":"Postantifungal effect of anidulafungin against Candida albicans, Candida dubliniensis, Candida africana, Candida parapsilosis, Candida metapsilosis and Candida orthopsilosis","volume":"32","author":"Eraso","year":"2019","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/jam.14490","article-title":"Sertraline as a promising antifungal agent: Inhibition of growth and biofilm of Candida auris with special focus on the mechanism of action in vitro","volume":"128","author":"Gowri","year":"2020","journal-title":"J. Appl. Microbiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000007296","article-title":"Influence of temperature and concentration on the postantifungal effect and the effects of sub-MIC concentrations of four antifungal agents on previously treated Candida species","volume":"46","author":"Llorente","year":"2000","journal-title":"Chemotherapy"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1439-0507.1991.tb00803.x","article-title":"In vitro comparative evaluations of the postantifungal effect: Synergistic interaction between flucytosine and fluconazole against Candida albicans","volume":"34","author":"Scalarone","year":"1991","journal-title":"Mycoses"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/02681219280000261","article-title":"Synergistic postantifungal effect of flucytosine and fluconazole on Candida albicans","volume":"30","author":"Mikami","year":"1992","journal-title":"J. Med. Vet. Mycol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF00436389","article-title":"Comparative studies on the postantifungal effect produced by the synergistic interaction of flucytosine and amphotericin B on Candida albicans","volume":"120","author":"Scalarone","year":"1992","journal-title":"Mycopathologia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v16.i6.20","article-title":"Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy","volume":"16","author":"Hoffman","year":"1999","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1128\/AAC.01030-07","article-title":"Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans","volume":"52","author":"Venisse","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11046-012-9554-7","article-title":"Comparison of in vitro and vivo efficacy of caspofungin against Candida parapsilosis, C. orthopsilosis, C. metapsilosis and C. albicans","volume":"174","author":"Foldi","year":"2012","journal-title":"Mycopathologia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1093\/jac\/dks180","article-title":"In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis","volume":"67","author":"Spreghini","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s11046-018-0302-5","article-title":"comparison of killing activity of micafungin against six candida species isolated from peritoneal and pleural cavities in RPMI-1640, 10 and 30% serum","volume":"183","author":"Kardos","year":"2018","journal-title":"Mycopathologia"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Kov\u00e1cs, R., T\u00f3th, Z., Locke, J.B., Forg\u00e1cs, L., Kardos, G., Nagy, F., Borman, A., and Majoros, L. (2021). comparison of in vitro killing activity of rezafungin, anidulafungin, caspofungin, and micafungin against four Candida auris clades in RPMI-1640 in the absence and presence of human serum. Microorganisms, 9.","DOI":"10.3390\/microorganisms9040863"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/00365549609037948","article-title":"Postantifungal effect and effects of low concentrations of amphotericin B and fluconazole on previously treated Candida albicans","volume":"28","author":"Lima","year":"1996","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000239455","article-title":"Influence of human serum on the postantifungal effect of four antifungal agents on Candida albicans","volume":"42","author":"Lima","year":"1996","journal-title":"Chemotherapy"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1159\/000516240","article-title":"Animal models in pharmacology: A brief history awarding the nobel prizes for physiology or medicine","volume":"106","author":"Oliveira","year":"2021","journal-title":"Pharmacology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1128\/AAC.47.4.1193-1199.2003","article-title":"In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model","volume":"47","author":"Andes","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1128\/AAC.47.4.1187-1192.2003","article-title":"In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model","volume":"47","author":"Andes","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/AAC.48.1.137-142.2004","article-title":"Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis","volume":"48","author":"Andes","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/AAC.01061-07","article-title":"In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model","volume":"52","author":"Andes","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1128\/AAC.01601-08","article-title":"Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: Mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect","volume":"53","author":"Warn","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s13318-013-0122-4","article-title":"Effective concentration-based serum pharmacodynamics for antifungal azoles in a murine model of disseminated Candida albicans infection","volume":"38","author":"Maki","year":"2013","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40121-020-00382-7","article-title":"Sixty years of amphotericin B: An overview of the main antifungal agent used to treat invasive fungal infections","volume":"10","author":"Cavassin","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.idc.2021.03.005","article-title":"Antifungals in clinical use and the pipeline","volume":"35","author":"Johnson","year":"2021","journal-title":"Infect. Dis. Clin. North Am."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/jac\/34.1.83","article-title":"The postantibiotic effect of antifungal agents against common pathogenic yeasts","volume":"34","author":"Turnidge","year":"1994","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1034\/j.1600-0714.2000.290503.x","article-title":"Sub-therapeutic exposure to polyene antimycotics elicits a post-antifungal effect (PAFE) and depresses the cell surface hydrophobicity of oral Candida albicans isolates","volume":"29","author":"Egusa","year":"2000","journal-title":"J. Oral Pathol. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1590\/1678-775720150100","article-title":"Impact of brief exposure to antifungal agents on the post-antifungal effect and hemolysin activity of oral Candida albicans","volume":"23","author":"Ellepola","year":"2015","journal-title":"J. Appl. Oral Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1600-0714.1999.tb02007.x","article-title":"The in vitro post-antifungal effect of nystatin on Candida species of oral origin","volume":"28","author":"Ellepola","year":"1999","journal-title":"J. Oral Pathol. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3109\/13693780903496583","article-title":"The post-antifungal effect (PAFE) of amphotericin B, nystatin, ketoconazole and 5-fluorocytosine and its impact on the colonization traits of Candida glabrata","volume":"48","author":"Samaranayake","year":"2010","journal-title":"Med. Mycol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1128\/AAC.43.9.2116","article-title":"Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model","volume":"43","author":"Andes","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_61","unstructured":"(2022, May 16). ClinicalTrial.gov Rezafungin, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=rezafungin&term=&cntry=&state=&city=&dist=."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice guideline for the management of candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1128\/AAC.46.12.3846-3853.2002","article-title":"In vitro activity of micafungin (FK-463) against Candida spp.: Microdilution, time-kill, and postantifungal-effect studies","volume":"46","author":"Ernst","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e01572-18","DOI":"10.1128\/AAC.01572-18","article-title":"Pharmacodynamic Evaluation of rezafungin (CD101) against Candida auris in the neutropenic mouse invasive candidiasis model","volume":"62","author":"Lepak","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e00546","DOI":"10.1002\/prp2.546","article-title":"Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK\/PD pharmacometrics of rezafungin efficacy","volume":"7","author":"Miesel","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1128\/AAC.44.4.938-942.2000","article-title":"In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model","volume":"44","author":"Andes","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1128\/AAC.49.12.5058-5068.2005","article-title":"Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: Importance of persistence of caspofungin in tissues to understanding drug activity","volume":"12","author":"Louie","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/1061186X.2020.1803333","article-title":"Coadministration of liposomal methylglyoxal increases the activity of amphotericin B against Candida albicans in leukopoenic mice","volume":"29","author":"Khan","year":"2021","journal-title":"J. Drug Target."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1128\/AAC.02681-15","article-title":"Cell wall changes in amphotericin B-resistant strains from Candida tropicalis and relationship with the immune responses elicited by the host","volume":"60","author":"Rueda","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jiac.2015.02.001","article-title":"Applications of the pharmacokinetic\/pharmacodynamic (PK\/PD) analysis of antimicrobial agents","volume":"21","author":"Isla","year":"2015","journal-title":"J. Infect. Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1517\/17425255.2016.1123250","article-title":"Pharmacokinetics and pharmacodynamics in antibiotic dose optimization","volume":"12","author":"Sy","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/QCO.0000000000000740","article-title":"Managing uncertainty in antifungal dosing: Antibiograms, therapeutic drug monitoring and drug-drug interactions","volume":"34","author":"Lewis","year":"2021","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/jac\/dkaa005","article-title":"Methodological features of clinical pharmacokinetic-pharmacodynamic studies of antibacterials and antifungals: A systematic review","volume":"75","author":"McAleenan","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/jac\/43.2.305","article-title":"Serum protein binding of itraconazole and fluconazole in patients with diabetes mellitus","volume":"43","author":"Arredondo","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/FTD.0000000000000095","article-title":"Determination of plasma unbound fraction of voriconazole in patients treated with a prophylactic or a curative treatment","volume":"36","author":"Florent","year":"2014","journal-title":"Ther. Drug Monit."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/jpp\/rgab157","article-title":"An in-vitro comparative study of the binding of caspofungin and micafungin to plasma proteins","volume":"74","author":"Yamasaki","year":"2022","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1185\/03007995.2012.761135","article-title":"Optimizing antifungal choice and administration","volume":"29","author":"Andes","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2147\/IDR.S198764","article-title":"Efficacy of humanized single large doses of caspofungin on the lethality and fungal tissue burden in a deeply neutropenic murine model against Candida albicans and Candida dubliniensis","volume":"12","author":"Perlin","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e01009-17","DOI":"10.1128\/AAC.01009-17","article-title":"Unraveling drug penetration of echinocandin antifungals at the site of infection in an intra-abdominal abscess model","volume":"61","author":"Zhao","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_80","unstructured":"(2022, May 18). CANCIDAS, INN-Caspofungin (as Acetate)\u2013Europa EU. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cancidas-epar-product-information_en.pdf."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1128\/AAC.05134-11","article-title":"Phase II dose escalation study of caspofungin for invasive aspergillosis","volume":"55","author":"Cornely","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1007\/s12325-019-01115-0","article-title":"Choosing the right antifungal agent in ICU patients","volume":"36","author":"Chatelon","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1128\/AAC.03736-14","article-title":"Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents","volume":"59","author":"Hope","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/bdd.752","article-title":"Higher clearance of micafungin in neonates compared with adults: Role of age-dependent micafungin serum binding","volume":"32","author":"Yanni","year":"2011","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000238478","article-title":"5-Fluorocytosine kinetics in patients with acute renal failure undergoing continuous hemofiltration","volume":"33","author":"Ittel","year":"1987","journal-title":"Chemotherapy"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1128\/AAC.00335-13","article-title":"Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy","volume":"57","author":"Weiler","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s13318-014-0204-y","article-title":"Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction","volume":"40","author":"Undre","year":"2015","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1128\/AAC.02942-15","article-title":"Population pharmacokinetics of isavuconazole in subjects with mild or moderate hepatic impairment","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/tid.12070","article-title":"Pharmacokinetics of micafungin in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Oshima","year":"2013","journal-title":"Transpl. Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1128\/AAC.00265-11","article-title":"Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients","volume":"56","author":"Young","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/FTD.0b013e31821fb197","article-title":"Posaconazole plasma concentrations in critically ill patients","volume":"33","author":"Ray","year":"2011","journal-title":"Ther. Drug Monit."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jcrc.2015.04.117","article-title":"Pharmacokinetics\/pharmacodynamics of micafungin in a surgical critically ill patient during extracorporeal carbon dioxide removal and continuous renal replacement therapy","volume":"30","author":"Maseda","year":"2015","journal-title":"J. Crit. Care"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13054-015-0758-3","article-title":"Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study","volume":"19","author":"Sinnollareddy","year":"2015","journal-title":"Crit. Care"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40262-016-0495-z","article-title":"Caspofungin population pharmacokinetics in critically ill patients undergoing continuous veno-venous haemofiltration or haemodiafiltration","volume":"56","author":"Roger","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","article-title":"Pharmacokinetics of antifungal drugs: Practical implications for optimized treatment of patients","volume":"45","author":"Bellmann","year":"2017","journal-title":"Infection"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1128\/AAC.00054-16","article-title":"Drug-drug interaction associated with mold-active triazoles among hospitalized patients","volume":"60","author":"Andes","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_97","unstructured":"European Committee on Antimicrobial Susceptibility Testing (2022, May 15). Antimicrobial Wild Type Distribution of Microorganism. Available online: https:\/\/mic.eucast.org\/Eucast2\/."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40265-018-0891-9","article-title":"Individualising therapy to minimize bacterial multidrug resistance","volume":"78","author":"Heffernan","year":"2018","journal-title":"Drugs"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"948","DOI":"10.15252\/msb.20177723","article-title":"Drug detoxification dynamics explain the postantibiotic effect","volume":"13","author":"Srimani","year":"2017","journal-title":"Mol. Syst. Biol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1128\/AAC.01430-10","article-title":"Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia","volume":"55","author":"Andes","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1080\/1120009X.2017.1289308","article-title":"Fungicidal activity and PK\/PD of caspofungin as tools to guide antifungal therapy in a fluconazole-resistant C. parapsilosis candidemia","volume":"29","author":"Tascini","year":"2017","journal-title":"J. Chemother."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/myc.13121","article-title":"From bench to bedside: Perspectives on the utility of pharmacokinetics\/pharmacodynamics in predicting the efficacy of antifungals in invasive candidiasis","volume":"63","author":"Pea","year":"2020","journal-title":"Mycoses"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"a019653","DOI":"10.1101\/cshperspect.a019653","article-title":"Antifungal pharmacokinetics and pharmacodynamics","volume":"5","author":"Lepak","year":"2014","journal-title":"Cold Spring Harb Perspect. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/FTD.0000000000000657","article-title":"Pharmacokinetic\/Pharmacodynamic analysis of voriconazole against Candida spp. and Aspergillus spp. in allogeneic stem cell transplant recipients","volume":"41","author":"Navarro","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/AAC.01584-09","article-title":"In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species","volume":"54","author":"Andes","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/jac\/dkx448","article-title":"We can do better: A fresh look at echinocandin dosing","volume":"73","author":"Bader","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.phrs.2018.07.005","article-title":"Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives","volume":"134","author":"Mouton","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.coph.2017.09.009","article-title":"Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selection","volume":"36","author":"Trang","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/cpt.2198","article-title":"Model-informed drug development for anti-infectives: State of the art and future","volume":"109","author":"Rayner","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.cmi.2020.05.037","article-title":"Antifungal therapeutic drug monitoring: Focus on drugs without a clear recommendation","volume":"26","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40268-021-00376-x","article-title":"Pharmacokinetics and Pharmacodynamics of Ibrexafungerp","volume":"22","author":"McCarthy","year":"2022","journal-title":"Drugs R D"},{"key":"ref_112","first-page":"906563","article-title":"In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study","volume":"16","author":"Hamprecht","year":"2022","journal-title":"Front Cell Infect. Microbiol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/mmy\/myz083","article-title":"Ibrexafungerp: A novel oral glucan synthase inhibitor","volume":"1","author":"Davis","year":"2020","journal-title":"Med. Mycol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/jac\/dkn129","article-title":"Post-antifungal effect of amphotericin B and voriconazole against germinated Aspergillus fumigatus conidia","volume":"61","author":"Chryssanthou","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jgar.2021.03.017","article-title":"Characterisation of the antifungal effects of a plant-based compound, CIN-102, on the main septal filamentous fungi involved in human pathology","volume":"25","author":"Tesse","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/jac\/dkg285","article-title":"Evaluation of the post-antifungal effect (PAFE) of amphotericin B and nystatin against 30 zygomycetes using two different media","volume":"52","author":"Vitale","year":"2003","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/8\/7\/727\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:49:11Z","timestamp":1760140151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/8\/7\/727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":116,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["jof8070727"],"URL":"https:\/\/doi.org\/10.3390\/jof8070727","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,12]]}}}